The two-day meeting will provide an opportunity for scientists from AstraZeneca, MedImmune and the Cambridge scientific community to discuss and present cutting-edge research on a variety of multi-disciplinary cancer research topics spanning pre-clinical, translational and clinical research.
The meeting will be hosted by:
Susan Galbraith, VP Head, AZ Oncology IMed
Tony Johnson, VP Head, AZ Early Clinical Development
Richard Gilbertson, Director, CRUK Cambridge Centre
The meeting will focus on Cancer Combination Therapies and will build on the themes that are being developed through collaborations between AstraZeneca, MedImmune, and the CRUK Cambridge Centre. The key cancer science topics to be covered are:
- Early phase design, scheduling and toxicity considerations for combinations
- Translational biomarkers and ctDNA for combinations
- Preclinical evaluation and screening for combinations
- Combinations in DDR and radiotherapy
- Combinations with immunotherapy
- Targeted therapy combinations
Aimed at PhD students, PostDocs and Group Leaders actively engaged in cancer research, the Symposium agenda is designed to enable you to network, make new contacts and identify new opportunities for collaboration.
Space is limited at the Symposium, therefore preference will be given to those who would like to present either a short (10 min) talk or poster. We would therefore encourage you to submit an abstract (maximum of 250 words) for either a talk or poster, when registering your interest.
Registration for this meeting has now closed but if you would like to submit an abstract please contact Katie.edwards@cruk.cam.ac.uk as we may be able to accept late submissions for some sessions.
